Form 4: Arteris Director Sells Shares Under 10b5-1 Plan

Director Saiyed Atiq Raza of Arteris, Inc. has sold a significant number of shares as part of a pre-established trading plan.

Summary

• Director Saiyed Atiq Raza reported the sale of 90,000 shares of common stock in Arteris, Inc. on May 1, 2026.
• The transaction was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.
• The sale occurred at a weighted average price of $28.713 per share, with individual transactions ranging from $28.07 to $29.33.
• Following the sale, the reporting person beneficially owns 210,000 shares, with 20,839 held directly and the remainder indirectly through a revocable trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale was conducted under a pre-arranged trading plan, indicating a planned divestment rather than a reaction to company performance.

Negatives

• Director Saiyed Atiq Raza sold 90,000 shares of common stock, representing a reduction in direct beneficial ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives and directors to diversify holdings or manage personal finances in a pre-determined manner, mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders may observe the sale of shares by a director, which could be interpreted in various ways, though the 10b5-1 plan mitigates concerns about adverse non-public information.

Key Dates

Keywords

Arteris Inc, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transaction, Beneficial Ownership